University of Pennsylvania Health System
Office of Public Affairs
399 South 34th Street, Suite 2002, Penn Tower, Philadelphia, PA 19104-5653

Ed Federico, (215) 349-5659,

June 17, 2004

Kyle Kampman, MD, Receives Caron Foundation Community Service Award for Work on Addiction Research

(Philadelphia, PA) – Kyle Kampman, MD, Associate Professor of Psychiatry at the University of Pennsylvania School of Medicine and Medical Director of the Treatment Research Center, will receive the Medical Professional Award – Physician, from the Caron Foundation. This prestigious, peer-nominated prize consists of a certificate and plaque. The not-for-profit Caron Foundation will honor Dr. Kampman, among other local individuals and organizations, at its Philadelphia Community Service Awards Breakfast to be held at the Union League of Philadelphia, Friday, June 18, 2004 from 8:00 AM until 9:00 AM.

“The Caron Foundation presents its Community Service Awards to those individuals or groups that have made a difference in the areas of addiction education, awareness or treatment,” says James McManus, regional Vice President for Caron Philadelphia. “We honor Dr. Kampman for his dedication to addiction research, specifically his work with cocaine addiction, which has contributed an impressive amount of knowledge in the area of withdrawal symptoms management.”

Addiction is a medically diagnosable disease that is chronic, progressive and potentially fatal. Current estimates show that chemical dependency and addiction affect 1 in 3 American families. Because of the prevalence of the problem, the Caron Foundation annually recognizes those who help others suffering from the disease of addiction.

Dr. Kampman earned his BA from Northwestern University and his MD from Tulane University. Dr. Kampman has conducted clinical research and published a number of papers on the treatment of addictive disorders. His current research interests include the evaluation and treatment of cocaine withdrawal symptoms. Dr. Kampman has developed a valid and reliable instrument called the Cocaine Selective Severity Assessment, a reliable predictor of outcome in outpatient cocaine dependence treatment.


PENN Medicine is a $2.5 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System (created in 1993 as the nation’s first integrated academic health system).

Penn’s School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report’s most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System consists of four hospitals (including its flagship Hospital of the University of Pennsylvania, consistently rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report), a faculty practice plan, a primary-care provider network, three multispecialty satellite facilities, and home health care and hospice.

Release available online at